Efficacy of pharmacological treatment in rheumatoid arthritis: A systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 79, Issue 6, 2020, Pages S744-S759

  Kerschbaumer, Andreas ^a   Sepriano, Alexandre ^b,c   Smolen, Josef S ^a   Van Der Heijde, Désirée ^b   Dougados, Maxime ^d   Van Vollenhoven, Ronald ^e   McInnes, Iain B ^f   Bijlsma, Johannes W J ^g   Burmester, Gerd R ^h   De Wit, Maarten ⁱ   Falzon, Louise ^j   Landewé, Robert ^e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NOVA MEDICAL SCHOOL   (Portugal)

^d université Paris Cité   (France)

^e Rheumatology and Clinical Immunology   (Netherlands)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ EULAR Standing Committee   (Switzerland)

^j Northwell Health   (United States)

more..

Author keywords

anti TNF; DMARDs (biologic); DMARDs (synthetic); rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; BARICITINIB; CERTOLIZUMAB PEGOL; CNTO 6785; DECERNOTINIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FILGOTINIB; GLUCOCORTICOID; GOLIMUMAB; GUSELKUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; JANUS KINASE INHIBITOR; LANRAPLENIB; LEFLUNOMIDE; MAVRILIMUMAB; METHOTREXATE; OLOKIZUMAB; OTILIMAB; PEFICITINIB; PLACEBO; REMTOLUMAB; RITUXIMAB; SALAZOSULFAPYRIDINE; SARILUMAB; SBI 087; SECUKINUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; DRUG; TUMOR NECROSIS FACTOR;

ARTICLE; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; COMBINATION DRUG THERAPY; DRUG SUBSTITUTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; JANUS KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYNTHETIC DRUGS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85079280201     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2019-216656     Document Type: Article

References (153)

1. Nam JL, Takase-Minegishi K, Ramiro S, et al. Efficacy of biological disease-modifying antirheumatic drugs: A systematic literature review Informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1113-36.
2. Chatzidionysiou K, Emamikia S, Nam J, et al. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: A systematic literature review Informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1102-7.
3. Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: A systematic literature review Informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1101-36.
4. Smolen JS, Burmester G-R, Combe B, et al. Head-To-Head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 2016;388:2763-74.
5. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international Task force. Ann Rheum Dis 2016;75:3-15.
6. Moller-Bisgaard S, Horslev-Petersen K, Ejbjerg B, et al. Effect of magnetic resonance imaging vs conventional Treat-To-Target strategies on disease activity remission and radiographic progression in rheumatoid arthritis: The IMAGINE-RA randomized clinical trial. JAMA 2019;321:461-72.
7. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
8. Sepriano A, Kerschbaumer A, Smolen JS, et al. Safety of synthetic and biological DMARDs: A systematic literature review Informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2020;79:747-57.
9. van der Heijde D, Aletaha D, Carmona L, et al. 2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8-13.
10. Verschueren P, De Cock D, Corluy L, et al. Effectiveness of methotrexate with step-down glucocorticoid remission induction (cobra slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-To-Target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis 2017;76:511-20.
11. Stouten V, Joly J, De Cock D. Sustained effectiveness after remission induction with methotrexate and step-down glucocorticoids in patients with early rheumatoid arthritis following a treat-To-Target strategy after 2 years. Arthritis and rheumatology Conference: American college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2017 United states, 2017.
12. Register KA, Cannella AC, Mikuls TR. Leflunomide, sulfasalazine and hydroxychloroquine for rheumatoid arthritis: efficacious but poorly tolerated. Arthritis and rheumatology Conference: American college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2016 United states Conference start: 20161111 Conference end: 20161116, 2016:2014-5.
13. Damjanov N, Tlustochowicz M, Aelion J, et al. Safety and efficacy of SBI-087, a subcutaneous agent for B cell depletion, in patients with active rheumatoid arthritis: results from a phase II randomized, double-blind, placebo-controlled study. J Rheumatol 2016;43:2094-100.
14. Mazurov V, Denisov L, Gordeev I, et al. SAT0206 Results of the alterra clinical trial-The efficacy of the alternative dosing regimen for rituximab biosimilar in bdmards naive patients with rheumatoid arthritis. Ann Rheum Dis 2018;77:963.
15. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and Nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol 2017;69:277-90.
16. Tanaka Y, Wada K, Takahashi Y. Efficacy and safety of sarilumab plus methotrexate in a phase 3 trial in Japanese patients with active rheumatoid arthritis (KAKEHASI). International journal of rheumatic diseases Conference: 20th asia pacific league of associations for rheumatology congress, APLAR 2018 Taiwan (republic of china), 2019:200.
17. Aletaha D, Bingham CO, Tanaka Y, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): A randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet 2017;389:1206-17.
18. Tanaka Y, Bingham C, Aletaha D. Sirukumab, an anti-IL-6 cytokine monoclonal antibody, significantly improves physical function and reduces morning stiffness in patients with active rheumatoid arthritis despite anti-TNF therapy: results from a global, randomized, placebo-controlled, phase 3 trial. Arthritis and rheumatology Conference: American college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2016 United states Conference start: 20161111 Conference end: 20161116, 2016:2008-9.
19. Takeuchi T, Thorne C, Karpouzas G, et al. Sirukumab for rheumatoid arthritis: The phase III SIRROUND-D study. Ann Rheum Dis 2017;76:2001-8.
20. Takeuchi T, Tanaka Y, Yamanaka H, et al. Efficacy and safety of olokizumab in Asian patients with moderate-To-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial. Mod Rheumatol 2016;26:15-23.
21. Dorner T, Weinblatt M, Van Beneden K, et al. FRI0239 results of a phase 2B study of vobarilizumab, an anti-interleukin-6 receptor nanobody, as monotherapy in patients with moderate to severe rheumatoid arthritis. Ann Rheum Dis 2017;76:575.
22. Weinblatt M, Dorner T, Zeldin R. Results of a phase IIb study of vobarilizumab, an anti-interleukin 6 receptor nanobody, in patients with moderate-To-severe rheumatoid arthritis despite treatment with methotrexate. Journal of rheumatology Conference: 72nd annual meeting of the canadian rheumatology association, CRA 2017 Canada, 2017:880.
23. Burmester GR, McInnes IB, Kremer J, et al. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis 2017;76:1020-30.
24. Buckley C, Campos JAS, Yakushin S, et al. A phase IIb dose-ranging study of anti-GM-CSF with methotrexate treatment in patients with rheumatoid arthritis (rA) and an inadequate response to methotrexate. Arthritis Rheumatol 2018;70:2166-7.
25. Gupta A, Zecchin C, Fisheleva E, et al. Exposure-efficacy analysis in DMARD inadequate response rheumatoid arthritis patients treated with GSK3196165 along with methotrexate. Arthritis Rheumatol 2018;70:2799.
26. Tahir H, Deodhar A, Genovese M, et al. Secukinumab in active rheumatoid arthritis after Anti-TNFá therapy: A randomized, double-blind placebo-controlled phase 3 study. Rheumatol Ther 2017;4:475-88.
27. Mease PJ, Jeka S, Jaller JJ, et al. CNTO6785, a fully human Antiinterleukin 17 monoclonal antibody, in patients with rheumatoid arthritis with inadequate response to methotrexate: A randomized, placebo-controlled, phase II, dose-ranging study. J Rheumatol 2018;45:22-31.
28. Dokoupilová E, Aelion J, Takeuchi T, et al. Secukinumab after anti-Tumour necrosis factor-á therapy: A phase III study in active rheumatoid arthritis. Scand J Rheumatol 2018;47:276-81.
29. van Vollenhoven RF, Keystone EC, Strand V, et al. Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. Ann Rheum Dis 2018;77:495-9.
30. Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study. Ann Rheum Dis 2017;76:1679-87.
31. Apsangikar P, Chaudhry S, Naik M, et al. A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate. Indian J Rheumatol 2018;13:84-9.
32. Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis 2018;69:914-21.
33. Jamshidi A, Gharibdoost F, Vojdanian M, et al. A phase III, randomized, two-Armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. Arthritis Res Ther 2017;19:168.
34. Alten R, Glover J, Matsunaga N, et al. OP0021 efficacy and safety results of a phase III study comparing fkb327, an adalimumab biosimilar, with the adalimumab reference product in patients with active rheumatoid arthritis. Ann Rheum Dis 2017;76:59.
35. Genovese MC, Glover J, Greenwald M, et al. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, phase III, double-blind study, and its open-label extension. Arthritis Res Ther 2019;21:281.
36. Genovese MC, Glover J, Matsunaga N. Efficacy, safety and immunogenicity in randomized, double-blind (DB) and open-label extension (OLE) studies comparing FKB327, an adalimumab biosimilar, with the adalimumab reference product (humira; RP) in patients (PTS) with active rheumatoid arthritis (rA). Arthritis and rheumatology Conference: American college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2017 United states, 2017.
37. Piotr W, Slawomir J, Eva D. A randomized, double-blind, parallel-group, multicenter study to compare the efficacy, safety and immunogenicity of a proposed adalimumab Biosimilar (GP2017) with reference adalimumab in patients with moderate-To-severe active rheumatoid arthritis. 2018 ACR/ARHP Annual Meeting; Arthritis & Rheumatology, Chicago, USA, 2018.
38. Fleischmann RM, Alten R, Pileckyte M, et al. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis. Arthritis Res Ther 2018;20:178.
39. Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III randomized study of SB5, an adalimumab Biosimilar, versus reference adalimumab in patients with moderate-To-severe rheumatoid arthritis. Arthritis Rheumatol 2018;70:40-8.
40. Jani RH, Gupta R, Bhatia G, et al. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis 2016;19:1157-68.
41. O?Dell J, Takeuchi T, Tanaka Y, et al. OP0226 Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept in Patients with Active Rheumatoid Arthritis (RA) despite Methotrexate (MTX) Therapy. Ann Rheum Dis 2016;75:143.1-143.
42. Matucci-Cerinic M, Allanore Y, Kavanaugh A, et al. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-To-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open 2018;4:e000757.
43. Bae S-C, Kim J, Choe J-Y, et al. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: The HERA study. Ann Rheum Dis 2017;76:65-71.
44. Matsuno H, Tomomitsu M, Hagino A, et al. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. Ann Rheum Dis 2018;77:488-94.
45. Lila A, Denisov L, Plaksina T. Efficacy and safety of BCD-055 (infliximab biosimilar) in rheumatoid arthritis. Results of BCD-055-3/lira phase 3 clinical study. Annals of the rheumatic diseases Conference: Annual european congress of rheumatology, EULAR 2018 Netherlands, 2018:316-7.
46. Lila AM, Mazurov VI, Denisov LN, et al. A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study. Rheumatol Int 2019;39:1537-46.
47. Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther 2016;18:82.
48. Matsuno H, Matsubara T. A randomized double-blind parallel-group phase III study to compare the efficacy and safety of NI-071 and infliximab reference product in Japanese patients with active rheumatoid arthritis refractory to methotrexate. Modern Rheumatology 2018;05:1-26.
49. Cohen SB, Alten R, Kameda H, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther 2018;20:155.
50. Choe J-Y, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing Sb2, an infliximab biosimilar, to the infliximab reference product remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017;76:58-64.
51. Smolen JS, Choe J-Y, Prodanovic N, et al. Comparing biosimilar Sb2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. Rheumatology 2017;56:1771-9.
52. Nasonov E, Mazurov V, Plaksina T. Interchangeability of innovator rituximab and its biosimilar: results from international controlled comparative 1-year study in patients with active rheumatoid arthritis. Arthritis and rheumatology Conference: American college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2016 United states Conference start: 20161111 Conference end: 20161116, 2016:2046-7.
53. Park W, Božic-Majstorovic L, Milakovic D, et al. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: A randomized controlled phase 3 trial. MAbs 2018;10:934-43.
54. Haridas V, Katta R, Nalawade A. Double-blind randomized parallel arm study of 3 anti CD20 monoclonal antibodies in patients with moderate to severe, sero-positive rheumatoid arthritis inadequately responding to metho-Trexate based therapy. Efficacy safety & immunogenicity results. Journal of rheumatology Conference: 73rd annual meeting of the canadian rheumatology association, CRA 2018 Canada, 2018:1052.
55. Smolen JS, Cohen SB, Tony H-P, et al. A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2017;76:1598-602.
56. Weinblatt ME, Baranauskaite A, Dokoupilova E, et al. Switching from reference adalimumab to SB5 (adalimumab Biosimilar) in patients with rheumatoid arthritis: Fifty-Two-Week phase III randomized study results. Arthritis Rheumatol 2018;70:832-40.
57. O?Dell J, Kivitz A, Takeuchi T, et al. SAT0162 switching from etanercept to CHS-0214: A one year, randomized, double-blind study in patients with rheumatoid arthritis. Ann Rheum Dis 2017;76:831.
58. Song YW, Matsuno H, Park MC, et al. Efficacy and safety of switching from etanercept product to LBEC0101 (etanercept biosimilar) compared with continuing LBEC0101 in patients with rheumatoid arthritis. Annals of the rheumatic diseases conference: Annual European Congress of rheumatology, EULAR 2018 Netherlands 2018;77:1389-90.
59. Park M-C, Matsuno H, Kim J, et al. Long-Term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: An open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. Arthritis Res Ther 2019;21:122.
60. Smolen JS, Choe J-Y, Prodanovic N, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar Sb2 compared with continuing reference infliximab and Sb2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Ann Rheum Dis 2018;77:234-40.
61. Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017;389:2304-16.
62. Porter D, van Melckebeke J, Dale J, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (orbit): An open-label, randomised controlled, non-inferiority, trial. Lancet 2016;388:239-47.
63. Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (monarch): A randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 2017;76:840-7.
64. Weinblatt ME, McInnes IB, Kremer JM, et al. A randomized phase IIb study of Mavrilimumab and golimumab in rheumatoid arthritis. Arthritis Rheumatol 2018;70:49-59.
65. Genovese MC, Weinblatt ME, Aelion JA, et al. ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17A, in patients with rheumatoid arthritis with an inadequate response to methotrexate: A randomized, double-blind study. Arthritis Rheumatol 2018;70:1710-20.
66. Taylor PC, Schiff MH, Wang Q, et al. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naive patients with active rheumatoid arthritis (SIRROUND-H): A randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. Ann Rheum Dis 2018;77:658-66.
67. Verschueren P, Emery P, Van Hoogstraten H, et al. Efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab. Annals of the rheumatic diseases conference: Annual European Congress of rheumatology, EULAR 2018 Netherlands 2018;77:327-8.
68. Gottenberg J-E , Brocq O, Perdriger A, et al. Non-TNF-Targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: A randomized clinical trial. JAMA 2016;316:1172-80.
69. Emery P, Bingham CO, Burmester GR, et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EA RLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis 2017;76:96-104.
70. Emery P, Tanaka Y, Bykerk VP. Efficacy and safety of abatacept in combination with MTX in early, MTX-N aive, Anti-Citrullinated protein Antibody-Positive patients with RA: primary and 1-year results from a phase IIIB study. 2018 ACR/ARHP Annual Meeting Chicago, USA; 2018 2018: Arthritis Rheumatol, 2018.
71. Stamm TA, Machold KP, Aletaha D, et al. Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: The DINORA trial. Arthritis Res Ther 2018;20.
72. Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled function trial. Ann Rheum Dis 2017;76:1279-84.
73. Fleischmann RM, Damjanov NS, Kivitz AJ, et al. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol 2015;67:334-43.
74. Genovese MC, Yang F, Ostergaard M, et al. Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings. Ann Rheum Dis 2016;75:1979-83.
75. Genovese MC, van Vollenhoven RF, Pacheco-Tena C, et al. VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol 2016;68:46-55.
76. Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: A 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis 2016;75:1057-64.
77. Genovese MC, Greenwald M, Codding C, et al. Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-To-severe rheumatoid arthritis. Arthritis Rheumatol 2017;69:932-42.
78. Kivitz AJ, Gutierrez-Urena SR, Poiley J, et al. Peficitinib, a JAK inhibitor, in the treatment of moderate-To-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol 2017;69:709-19.
79. Tanaka Y, Takeuchi T, Tanaka S. Efficacy and safety of the novel oral Janus kinase (JAK) inhibitor, Peficitinib (ASP015K), in a phase 3, double-blind, placebo-controlled, randomized study of patients with RA who had an inadequate response to Dmards. 2018 ACR/ARHP Annual Meeting Chicago, USA; 2018: Arthritis & Rheumatology, 2018.
80. Takeuchi T, Tanaka Y, Tanaka S. Efficacy and safety of the novel oral Janus kinase (JAK) inhibitor, peficitinib (ASP015K), in a phase 3, double-blind, placebo-controlled, randomized study of patients with RA who had an inadequate response to methotrexate. 2018 ACR/ARHP annual meeting Chicago, USA; 2018, 2018.
81. Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis 2019;78:1305-19.
82. Tanaka Y, Takeuchi T, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: A randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis 2019;78:1320-32.
83. Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (Darwin 1). Ann Rheum Dis 2017;76:998-1008.
84. Kivitz A, Mehta D, Matzkies F. GS-9876, a novel, highly selective, Syk inhibitor in patients with active rheumatoid arthritis: safety, tolerability and efficacy results of a phase 2 study. 2018 ACR/ARHP Annual Meeting Chicago, USA: Arthritis & Rheumatology, 2018.
85. Dougados M, van der Heijde D, Chen Y-C, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017;76:88-95.
86. Genovese M, Van Der Heijde D, Dougados M. Baricitinib inhibits radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis (rA) and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS). Internal medicine journal Conference: new zealand rheumatology association and australian rheumatology association with the rheumatology health professionals association joint annual scientific meeting New zealand, 2017:32.
87. Hu J, Bao C, Li X. Efficacy and safety of baricitinib in MTX-IR patients with rheumatoid arthritis: 52 week results from a phase 3 study (RA-balance). Annals of the rheumatic diseases conference: Annual European Congress of rheumatology, EULAR 2018 Netherlands, 2018:969-70.
88. Yue Y, Hu J, Bao C. Patient-Reported outcomes from a phase 3 study (RA-BALANCE) of baricitinib versus placebo in rheumatoid arthritis. International journal of rheumatic diseases Conference: 20th asia pacific league of associations for rheumatology congress, APLAR 2018 Taiwan, 2018:40.
89. Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 2017;69:506-17.
90. Schiff M, Takeuchi T, Fleischmann R, et al. Patient-Reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Res Ther 2017;19:208.
91. van Vollenhoven R, Takeuchi T, Pangan AL. A phase 3, randomized, controlled trial comparing Upadacitinib monotherapy to MTX monotherapy in MTX-N aive patients with active rheumatoid arthritis. ACR Meeting Abstracts. 2018 ACR/ARHP Annual Meeting Chicago, USA, 2018.
92. Smolen J, Cohen S, Emery P. Upadacitinib as monotherapy: A phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate. Annals of the rheumatic diseases conference: Annual European Congress of rheumatology, EULAR 2018 Netherlands, 2018:67-8.
93. Smolen J, Cohen S, Emery P. Upadacitinib as monotherapy: A phase 3 randomized controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate. 2018 ACR/ARHP Annual Meeting Chicago, USA, 2018.
94. Strand V, Buch M, Tundia N. Upadacitinib monotherapy improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to methotrexate. 2018 ACR/ARHP Annual Meeting Chicago, USA, 2018.
95. Tanaka Y, Takeuchi T, Yamaoka K. A phase 2B/3 randomised, placebo-controlled, double-blind study of upadacitinib, a selective JAK1 inhibitor, in Japanese patients with active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs. Annals of the rheumatic diseases conference: Annual European Congress of rheumatology, EULAR 2018 Netherlands, 2018:991-2.
96. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NE XT): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:2503-12.
97. Strand V, Pope J, Tundia N. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs: results from selectnext. Annals of the rheumatic diseases conference: Annual European Congress of rheumatology, EULAR 2018 Netherlands, 2018:989-90.
98. Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): A randomised, placebo-controlled, double-blind phase 3 study. Lancet 2019;393:2303-11.
99. Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial. Lancet 2018;391:2513-24. 06 23.
100. Strand V, Schiff M, Tundia N. Patient reported outcomes of upadacitinib: results from biologic inadequate responders (select beyond phase III trial). Annals of the rheumatic diseases Conference: Annual european congress of rheumatology, EULAR 2018 Netherlands, 2018:990.
101. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017;376:652-62.
102. Keystone EC, Taylor PC, Tanaka Y, et al. Patient-Reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis 2017;76:1853-61.
103. Strand V, Mysler E, Moots RJ. Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: patient-reported outcomes from a phase 3b/4 randomised trial. Annals of the rheumatic diseases conference: Annual European Congress of rheumatology, EULAR 2018 Netherlands, 2018:990-1.
104. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (oral strategy): A phase 3b/4, double-blind, head-To-head, randomised controlled trial. Lancet 2017;390:457-68.
105. Fleischmann R, Pangan AL, Mysler E. A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate. 2018 ACR/ARHP annual meeting Chicago, USA; 2018, 2018.
106. Fleischmann R, Pangan AL, Song I-H, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 2019;71:1788-800.
107. Kaeley GS, Evangelisto AM, Nishio MJ, et al. Methotrexate dosage reduction upon adalimumab initiation: clinical and ultrasonographic outcomes from the randomized noninferiority MUSICA trial. J Rheumatol 2016;43:1480-9.
108. Pope J, Rampakakis E, Grant E. DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs: interim results from a Canadian observational randomized study. Annals of the rheumatic diseases Conference: Annual european congress of rheumatology, EULAR 2017 Spain, 2017:58.
109. Pope JE, Rampakakis E, Vaillancourt J. DMARD Withdrawal in RA Patients Achieving Therapeutic Response with Certolizumab Pegol Combined with Dmards: Results from a Canadian Randomized Study-ACR Meeting Abstracts. 2018 ACR/ARHP Annual Meeting Chicago, USA, 2018.
110. Pope J, Rampakakis E, Vaillancourt J, et al. An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs. Rheumatology 2019;9.
111. Burmester GR, Buttgereit F, Bernasconi C. A randomized controlled 24-week trial evaluating the safety and efficacy of blinded tapering versus continuation of long-Term prednisone (5 mg/day) in patients with rheumatoid arthritis who achieved low disease activity or remission on tocilizumab. 2018 ACR/ARHP annual meeting Chicago, USA, 2018.
112. Pablos JL, Navarro F, Blanco FJ, et al. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: The randomised JUST-A CT study. Clin Exp Rheumatol 2019;37:437-44.
113. Kremer JM, Rigby W, Singer NG, et al. Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomized, controlled trial. Arthritis Rheumatol 2018;70:1200-8.
114. Edwards CJ, Östör AJK, Naisbett-Groet B, et al. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: A randomized, double-blind trial. Rheumatology 2018;57:84-91.
115. Stouten V, Michiels S, Belba A. Effectiveness of a randomized step-down to methotrexate or leflunomide maintenance therapy in patients with low disease activity, 40 weeks after starting combined methotrexate-leflunomide remission induction therapy in early rheumatoid arthritis: results from the carera trial. Annals of the rheumatic diseases conference: Annual European Congress of rheumatology, EULAR 2018 Netherlands, 2018:967-8.
116. Stouten V, Westhovens R, Pazmino S, et al. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: Two-year results of CareRA. Rheumatology 2019;58:2284-94.
117. Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, et al. Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: A pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 2016;68:1810-7.
118. Ghiti Moghadam M, ten Klooster PM, Vonkeman HE, et al. Impact of stopping tumor necrosis factor inhibitors on rheumatoid arthritis patients? burden of disease. Arthritis Care Res 2018;70:516-24.
119. Atsumi T, Tanaka Y, Yamamoto K, et al. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Ann Rheum Dis 2017;76:1348-56.
120. Weinblatt ME, Bingham CO, Burmester G-R, et al. A phase III study evaluating continuation, tapering, and withdrawal of Certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis Rheumatol 2017;69:1937-48.
121. Kaneko Y, Kato M, Tanaka Y, et al. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the surprise study). Ann Rheum Dis 2018;77:1268-75.
122. Ibrahim F, Lorente-Cánovas B, Doré CJ, et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-A proof of principle and exploratory trial: is dose tapering practical in good responders? Rheumatology 2017;56:2004-14.
123. Urata Y, Abe S, Devers B. A novel dose reduction therapy using biological disease-modifying anti-rheumatic drugs to target matrix metalloproteinase 3 normalization together with a simplified disease activity index 3.3 yields effects non-inferior to standard care in rheumatoid arthritis with regards maintaining remission. Annals of the rheumatic diseases Conference: Annual european congress of rheumatology of the european league against rheumatism, EULAR 2016 United kingdom Conference start: 20160608 Conference end: 20160611, 2016:204-5
124. l?Ami MJ, Krieckaert CL, Nurmohamed MT, et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: An open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis 2018;77:484-7.
125. Takeuchi T, Genovese MC, Haraoui B, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis 2019;78:171-8.
126. Akdemir G, Heimans L, Bergstra SA, et al. Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: improved study. Ann Rheum Dis 2018;77:111-8.
127. El Miedany Y, El Gaafary M, Youssef S, et al. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clin Rheumatol 2016;35:2915-23.
128. Van Mulligen E, Weel A, Kuijper TM. Gradual tapering TNF blockers versus conventional synthetic dmards in patients with rheumatoid arthritis in sustained remission: first year results of the randomised controlled tara-study. Annals of the rheumatic diseases Conference: Annual european congress of rheumatology, EULAR 2018 Netherlands, 2018:107.
129. Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis 2019;78:1454-62.
130. Shin K, Baek HJ, Kang YM, et al. Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate. Int J Rheum Dis 2019;22:1115-22.
131. Stamp LK, O?Donnell JL, Frampton C, et al. A pilot randomized controlled double-blind trial of high-versus low-dose Weekly folic acid in people with rheumatoid arthritis receiving methotrexate. J Clin Rheumatol 2019;25:284-7.
132. Bi L, Li Y, He L, et al. Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate Responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study. Clin Exp Rheumatol 2019;37:227-34.
133. Smolen JS, Agarwal SK, Ilivanova E, et al. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann Rheum Dis 2017;76:831-9.
134. Takeuchi T, Yamanaka H, Harigai M, et al. Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: A randomized phase 3 safety and efficacy study in Japanese patients. Arthritis Res Ther 2018;20:42.
135. Matsubara T, Inoue H, Nakajima T, et al. Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: A randomised placebo-controlled phase IV study. RMD Open 2018;4:e000813.
136. Tanaka Y, Wada K, Takahashi Y, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther 2019;21:79.
137. Strand V, Gossec L, Proudfoot CWJ, et al. Patient-Reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Arthritis Res Ther 2018;20:129.
138. Blanco FJ, Möricke R, Dokoupilova E, et al. Secukinumab in active rheumatoid arthritis: A phase III randomized, double-blind, active Comparator-And placebo-controlled study. Arthritis Rheumatol 2017;69:1144-53.
139. Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: function, a randomised controlled trial. Ann Rheum Dis 2016;75:1081-91.
140. Oba K, Horie N, Sato N, et al. Remission induction by raising the dose of remicade in RA (RRRR) study: rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. Contemp Clin Trials Commun 2017;8:49-54.
141. Tanaka Y, Oba K, Koike T, et al. Sustained clinical remission after discontinuation of infliximab with a raising dose strategy in patients with rheumatoid arthritis (RRRR study): A randomized controlled trial. Arthritis and Rheumatology 2018;70:3170-2.
142. Chatzidionysiou K, Turesson C, Teleman A, et al. A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open 2016;2:e000133.
143. Emery P, Burmester GR, Bykerk VP, et al. Re-Treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the avert study. RMD Open 2019;5:e000840.
144. Keystone EC, Pope JE, Thorne JC, et al. Two-Year radiographic and clinical outcomes from the Canadian methotrexate and etanercept outcome study in patients with rheumatoid arthritis. Rheumatology 2016;55:327-34.
145. Bouman CA, van Herwaarden N, van den Hoogen FH, et al. Long-Term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study-A randomised controlled pragmatic non-inferiority strategy trial. Ann Rheum Dis 2017;76:1716-22.
146. Mueller R, Spaeth M, von Restorff C, et al. Superiority of a Treat-To-Target strategy over conventional treatment with fixed csDMARD and corticosteroids: A multi-center randomized controlled trial in RA patients with an inadequate response to conventional synthetic DMARDs, and new therapy with Certolizumab pegol. J Clin Med 2019;8:302.
147. Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (Darwin 2). Ann Rheum Dis 2017;76:1009-19.
148. Genovese M, Westhovens R, Meuleners L, et al. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther 2018;20:57.
149. Tanaka Y, Sugiyama N, Toyoizumi S, et al. Modified-versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: A randomized, phase III, non-inferiority study. Rheumatology 2019;58:70-9.
150. van der Heijde D, Strand V, Tanaka Y, et al. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic and safety outcomes from the 24-month phase 3 oral scan study. Arthritis Rheumatol 2019;22:22.
151. Smolen JS, Kremer JM, Gaich CL, et al. Patient-Reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis 2017;76:694-700.
152. van der Heijde D, Dougados M, Chen Y-C, et al. Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open 2018;4:e000662.
153. Jaworski J, Matucci-Cerinic M, Schulze-Koops H, et al. Switch from reference etanercept to SDZ ETn, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-To-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Res Ther 2019;21:130.